A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Viswatej Avutu(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Travis E. Adamson(Memorial Sloan Kettering Cancer Center), Aimeé M. Crago(Memorial Sloan Kettering Cancer Center), Sinchun Hwang(Memorial Sloan Kettering Cancer Center), Sam S. Yoon(Columbia University Irving Medical Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Karissa Whiting(Memorial Sloan Kettering Cancer Center), Allison L. Richards(Memorial Sloan Kettering Cancer Center), Jason E. Chan(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Joseph P. Erinjeri(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Sujana Movva(Memorial Sloan Kettering Cancer Center), Mary Louise Keohan(Roche (Switzerland)), Samuel Singer(Memorial Sloan Kettering Cancer Center), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Edmund K. Bartlett(Memorial Sloan Kettering Cancer Center), Li‐Xuan Qin(Memorial Sloan Kettering Cancer Center)
Cited by 71
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k